Rezatapopt monotherapy generated a 33% overall response rate in 97 patients with solid tumors spanning across eight different cancers (ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma) and a median duration of response of 6.2 months, according to PYNNACLE phase II clinical trial interim data. These were patients whose tumors were TP53 Y220C mutated and KRAS wild-type.
Researchers at Moffitt Cancer Center have been awarded a $22.4 million grant from the U.S. Department of War to lead studies and clinical trials for leptomeningeal disease, a devastating complication of breast and other cancers that spreads to the coverings of the brain and spinal cord.
